ERBB2 and breast carcinoma: This pro-metastatic activity promoted by HER-2 could explain how the HER-2 amplification event may contribute to clinically late-stage disease and to the particularly aggressive behavior of HER-2 positive tumors [5-7] in addition to its role in breast cancer initiation.